FARMINGDALE, N.Y., Aug. 10, 2016 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced a partnership with SonoSpine, LLC (“SonoSpine”), an international neurosurgical practice specializing in ultrasonic spine surgery (www.sonospinesurgery.com). Misonix’s innovative ultrasonic devices paired with SonoSpine’s revolutionary approach to spine surgery is expected to accelerate the development and application of next generation ultrasonic surgery.
“Innovation is the key driver in improving patient outcomes. We are proud to collaborate with Misonix as we continue to develop and implement ultrasonic surgical tools and techniques for the spine which dramatically improve patient outcomes,” said Dr. Dilantha B. Ellegala, founder and surgeon-in-chief of SonoSpine. Misonix and SonoSpine share mutual corporate cultures which are committed to pioneering higher quality health care through technological innovation. This exclusive agreement will align these values to accelerate the development of such technologies. Moreover, our concentrated and unified efforts will promote broader and responsible adoption of these technological advances.”
A joint clinical database will support Misonix’s development of next generation devices while providing critical metrics for SonoSpine’s continued success in improving patient care. Access to SonoSpine’s clinical facilities allows new opportunities for Misonix to engineer from the surgeon’s perspective within the operating suite. To widen the framework of ultrasonic therapies, plans include joint device development, clinical outcomes evaluation, and a shared ultrasonic training facility where key opinion leaders and researchers can meet to fully leverage SonoSpine’s surgical approach and tap into Misonix’s extensive research and product development capabilities.
“This strategic partnership that we’ve entered into with Dr. Ellegala, and his team at SonoSpine, is an important milestone for Misonix. Our engineers and marketing team, working in close concert with the SonoSpine surgeons, will not only create best-in-class innovative ultrasonic surgical instruments, but also collaborate on the development of entirely new surgical procedures and techniques that would otherwise not be possible,” concluded Scott Ludecker, Senior Vice President of Global Sales and Marketing with Misonix.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.